Meheco Gets Supplementary Approvals for Clindamycin Phosphate Injection

MT Newswires Live
2025/07/08

China Meheco Group (SHA:600056), through subsidiary Tianfang Pharmaceutical, received two drug supplementary approvals for clindamycin phosphate injection after passing the Chinese drug regulator's consistency evaluation for quality and efficacy, according to a Shanghai bourse filing on Tuesday.

The approvals are for the drug's two specifications 4 milliliters and 2 milliliters.

The drug is used to treat serious infections caused by susceptible anaerobic bacteria, the filing said.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10